Other

Depuy Spine, Inc.

Ethicon, Gmbh

Janssen Pharmaceutica Nv

Johnson & Johnson Consumer Products, Inc.

Jeffrey C Geesin

Hassan A Serhan

Thomas M DiMauro

Richard A Berg

Mohamed Attawia

Sudhakar Kadiyala

David J Urbahns

Laura Brown

Anna Gosiewska

Sridevi N Dhanaraj

Scott Bruder

Jean Xu

Angelo G Scopelianos

Agnieszka Seyda

Jackie J Donners

Ian Ross Harris

Curtis A Cole

Stephen J Wisniewski

Dhanuraj Shetty

David C Colter

Charito S Buensuceso

Gregory Collins

Jeff Yon

Robert Gordon

Dhanaraj Sridevi

A tissue engineering construct made from a nonwoven fabric. The fabric is made from first and second staple fibers. The first staple fibers are made from a first biocompatible, bioabsorbable material, and the second staple fibers are made from a second biocompatible, bioabsorbable material. The first material has a melting temperature lower than the second material. The fabric is formed into a three-dimensional construct suitable for the repair of urinary tract structures.

Device and method for repair of urological structures

The present invention relates to administering a doxycycline compound into a diseased intervertebral disc.

Transdiscal administration of cycline compounds

The present invention relates to injecting a cycline compound into a diseased intervertebral disc.

There is provided a novel use for vascular endothelial growth factor, herein designated VEGF-X, and a CUB domain present in the sequence of VEGF-X, which enhance smooth muscle cell proliferation and can be used to treat diseases associated with reduced smooth muscle cell proliferation. VEGF-X, and a CUB domain can also be used in tissue engineering applications to increase the number of smooth muscle cells within specific tissue to restore that tissue function or architecture. Screening methods for identifying inhibitors of VEGF-X biological activity are also disclosed and these inhibitors include neutralizing VEGF-X antibodies, antisense VEGF-X sequences or non-protein antagonists competing with VEGF-X biological activity. Also provided are therapeutic methods for treating disorders associated with smooth muscle cells hyperproliferation and methods of diagnosis a pathological condition or susceptibility to a pathological condition associated with smooth muscle cell hyperproliferation.

Modulation of smooth muscle cell proliferation

The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.

Transdiscal administration of high affinity anti-MMP inhibitors

A novel method has been developed for screening anti-scarring and anti-fibrotic agents. This method offers simplicity, it is reproducible and could be adopted to screen large numbers of new potential ant-fibrotic agents. This method has characteristics in common with the BAEC/BASMC co-culture system, but is more sensitive and does not require screening large number of clonal lines for developing an effective method. In this system, similar to the co-culture system, activation of L-TGF-&bgr;1 occurs by several independent mechanisms which involve binding of the latent complex to M6P/IGF-II receptors, thrombospondin and/or tissue type II transglutaminase. But, in contrast to the co-culture system, this macrophage-dependent system does not appear to involve plasmin. Using this method, potential novel anti-fibrotic agents such as IGF-II, (used separately or in combination with IGFBP-2 as a delivery vehicle) tissue type II transglutaminase inhibitors and anti-inflammatory agents (such as hydrocortisone) were identified. A potential novel mechanism of action for Mannose 6-Phosphate has been proposed which is based on downregulation of M6P/IGF-II receptor and TGF-&bgr;1 mRNAs.

Anti-fibrotic agent assay

This invention relates to a skin model system that can be used as an in vitro test system or which can be used for therapeutic purposes. The skin model system comprises a three-dimensional, cross-linked matrix of insoluble collagen containing fibroblast cells therein, and stratified layers of differentiated epidermal cells supported thereon.

Skin model system

Dermal-epidermal in vitro test system

The present invention relates to a method of protecting skin from the oxidative effects of ultraviolet A radiation including UVA-induced lipid peroxidation. The method comprises topically applying to the skin an effective amount of a photoprotective composition that contains a lipophilic antioxidant that does not have appreciable absorbance near wavelengths of 320-380 nm.

Photoprotective lipophilic antioxidant compounds and their use to

Growing community of inventors

Doylestown, PA, United States of America

Jeffrey C Geesin